<DOC>
	<DOCNO>NCT02723669</DOCNO>
	<brief_summary>This study evaluate relative bioavailability Acetylcysteine Effervescent Tablets ( AR10 ) Reference N-acetylcysteine . Patients receive product Open Label , Randomized , Two-Arm , Single-Dose , Two-Period , Crossover design .</brief_summary>
	<brief_title>Relative Bioavailability AR10 Compared Reference Product</brief_title>
	<detailed_description>An Open Label , Randomized , Two-Arm , Single-Dose , Two-Period , Crossover Study Relative Bioavailability Study . The present study intend compare evaluate relative bioavailability single 11 gram dose AR10 ( acetylcysteine effervescent tablet oral solution ( two 0.5 g four 2.5 g ] ) , reference Listed Drug ( acetylcysteine solution ; oral 20 % [ 200 mg/mL ] American Pharmaceutical Partners ) healthy adult , human subject fast condition . A balanced block randomization schedule generate start dosing .</detailed_description>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Subjects ( male female ) 18 50 year age inclusive . Body weight least 154 pound ( 70 kg ) Body Mass Index great 30 kg/m2 . Healthy determine medical history , clinical examination , laboratory examination perform within 30 day prior admission first period study . Subjects willing able provide write informed consent , HIPPA adhere protocol requirement . If female childbearing potential ( define premenopausal female biologically capable become pregnant ) , subject must agree remain abstinent practice medically acceptable form contraception screen close visit clinical study . Acceptable form contraception include intrauterine device , implantable device , barrier method . If barrier method chosen , double barrier ( e.g. , condom plus foam ) require . Negative beta human chorionic gonadotropin test , consistent pregnancy ( female ) . Nonsmokers Known hypersensitivity , allergy , idiosyncratic reaction adverse reaction acetylcysteine , excipients , relate compound similar chemical characteristic severe allergic reaction drug multiple food/drug allergy . History current evidence clinically significant medical condition include , limited , hepatic , renal , cardiac , vascular , gastrointestinal , thyroid disease , diabetes , epilepsy , respiratory hematological disease , acute narrow angle glaucoma , psychiatric disorder , opinion Principal Investigator , would confound study result present risk subject . Subjects without symptom nausea and/or vomit . Subjects history chronic nausea/vomiting exclude . Subjects acute illness/condition nausea and/or vomit episode past two week may screen provide medically clear acute illness/condition involve nausea and/or vomit episode ( ) . Existence surgical medical condition judgment Principal Investigator might interfere absorption , distribution , metabolism , elimination investigational product . Any clinically significant abnormality electrocardiogram ( 12 lead ECG ) . Laboratory value consider clinically significant ( clinical chemistry , hematology , coagulation , urinalysis , pregnancy test ) Note : In event parameter lie outside normal range , sample may repeat . This value accept lie within normal range . Consumption grapefruit juice/grapefruit within 14 day prior Period I admission . Use alcohol caffeine containing product within 72 hour dose °History presence alcoholism drug abuse within 1 year study participation . Known suspected carcinoma . Presence disease marker human immunodeficiency virus ( HIV ) 1 2 , hepatitis B C virus . Positive serum test drug ( ) abuse test ( amphetamine , barbiturate , benzodiazepine , tetrahydrocannabinol , morphine , cocaine , alcohol ) . History intake/administration investigational treatment clinical study within last 30 day prior onset study admission Period I . History significant blood loss ( ≥ 350 mL ) due reason , include blood donation , within last 12 week prior admission Period I study . Intake/administration enzymemodifying drug drug might increase decrease acetylcysteine level within 30 day investigational product administration , overthecounter ( OTC ) drug include vitamin natural supplement within 21 day first dose Investigational Product administration throughout study unless approve Principal Investigator Sponsor . Requirement special diet prevent consumption standard , healthy meal inclinic portion study . In case , subject selection discretion Principal Investigator discussion Medical Monitor , require . Any subject , opinion Principal Investigator , may follow instruction . Difficulty swallow liquid solution . Female subject selfreported history anemia menstrual cycle may coincide dose day ( ) study period . Pregnant lactating female . Employee Sponsor , Clinical site , Clinical research organization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Relative Bioavailability</keyword>
</DOC>